| |
AbCellera is leveraging its T-cell engager platform to generate molecules with potent tumor-cell killing and reduced cytokine release for multiple tumor targets, including peptide-MHCs. Explore more. 
|
|
Today’s Big NewsMay 3, 2024 |
|
Tuesday, May 14, 2024 | 9:30am ET / 6:30am PT This webinar dives into patient-derived organoids viewed as the gold standard in bridging the gap between the lab and the clinic. The oncology portfolio allows researchers to incorporate patient relevance at every stage of the drug development pipeline - from target discovery and hit identification to lead validation and optimization. Register now. 
|
|
| By Gabrielle Masson Amgen is axing obesity candidate AMG 786 and going all in on later-stage asset MariTide. |
|
|
|
By Max Bayer CG Oncology’s late-stage bladder cancer treatment notched a complete response in roughly three-quarters of treated patients, fueling optimism that the company’s Wall Street success story is no fluke. |
By James Waldron Medicxi co-founder Francesco De Rubertis pointed to the current popularity of secondary stock offerings as a sign that “investors are excited.” |
By Max Bayer,Gabrielle Masson BridgeBio's oncology leaders will take the helm of a new cancer-focused spinout. Ipsen taps new North America chief two months after latest FDA nod. Ironwood's former CEO will lead George Medicines. |
By Ayla Ellison,Kevin Dunleavy This week on "The Top Line," we're diving into the details of the spree of big-money biopharma deals in 2023 and examining what that means for this year. |
By Fraiser Kansteiner Moderna currently expects initial approvals of its RSV vaccine to start rolling in during the first half of 2024, the company said Thursday. In turn, the company is eyeing a potential U.S. launch in the fall, which would capitalize on its established commercial efforts in the seasonal COVID-19 immunization market. |
By Conor Hale The U.S. Preventive Services Task Force officially updated its recommendations this week for who should be screened for breast cancer and when but did not go as far as some had hoped. |
By Angus Liu Japan's Ono will buy kinase inhibitor expert Deciphera for $2.4 billion. Novartis invests further in radiopharmaceuticals with two deals. WuXi Biologics has withdrawn from the 2024 BIO International Convention as the U.S. grows hostile against certain Chinese biotech companies. And more. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we're diving into the details of the spree of big-money biopharma deals in 2023 and examining what that means for this year. |
|
|---|
|
|
Whitepaper This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
Whitepaper Discover the secrets behind successful patient engagement Sponsored by: ProofPilot |
Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
eBook Unlock the future of monoclonal antibody (mAb) manufacturing with a complete guide to enhancing productivity and quality for exceptional outcomes. Sponsored by: Thermo Fisher Scientific |
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
